Search

   IDM overview                        YouTube

Home > Members > Full members > Mark Hatherill
Full Members

Professor Mark Hatherill, MBChB DCH MRCP FCPaed MMed MD

South African Tuberculosis Vaccine Initiative (SATVI)

Mark Hatherill

Director of South African Tuberculosis Vaccine Initiative (SATVI) & Full Member of the Institute of Infectious Disease and Molecular Medicine (IDM), Division of Immunology, Department of Pathology, Faculty of Health Sciences, UCT

SATVI is a world leader in TB vaccine clinical research. Their mission is the development of new and effective vaccination strategies against tuberculosis (TB). They are testing multiple new vaccine candidates in clinical trials; and are involved with projects to address critical clinical, epidemiological, immunological and human genetic questions in TB vaccine development. Activities are within an academic context, and thus include the training of postgraduate students. 

The team of over 100 staff consists of specialists in: clinical, epidemiological, human genetic and immunologic science, clinical trials, community liaison, recruitment and follow-up; data management and analysis, disease surveillance, information technology, clinical evaluation and care of participants; facility management, laboratory technology, logistics, research pharmacy management, project management, regulatory affairs, administration, study coordination and training. 

A/Professor Hatherill’s clinical research interests have focused on design, implementation, and analysis of clinical trials of BCG vaccine and novel TB vaccines candidates; diagnostic studies of TB infection and disease in adult and paediatric study populations; and TB therapeutic clinical trials. A major new project will test targeted TB preventive therapy for high risk persons identified by a novel transcriptomic correlate of risk assay.

Further details are found here [www.satvi.uct.ac.za]

 


Selected publications: 

  1. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, Oshea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas Z-R, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications (2016) 7:11290.

  2. Hatherill M, Scriba TJ, Udwadia ZF, Mullerpattan JB, Hawkridge A, Mahomed H, Dye C. BCG and new preventive tuberculosis vaccines: implications for healthcare workers. Clinical Infectious Diseases (2016) 62:S262-S267.

  3. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. The Lancet (2016) 387(10035):2312-2322.

  4. Tameris MD*, Hatherill M*, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; the MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; S0140-6736(13)60177-4.
     
  5. Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M*, Cangelosi GA*. Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients. Scientific Reports. 2015 Mar 2;5:8668. doi: 10.1038/srep08668
     
  6. Andrews JR, Hatherill M, Mahomed H, Hanekom WA, Campo M, Hawn TR, Wood R, Scriba TJ. The Dynamics of QuantiFERON®-TB Gold In-Tube Conversion and Reversion in a Cohort of South African Adolescents. Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91. doi: 10.1164/rccm.201409-1704OC.
     
  7. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056
     
  8. Johnson JL, Geldenhuys H, Thiel BA, Toefy A, Suliman S, Pienaar B, Chheng P, Scriba T, Boom WH, Hanekom W, Hatherill M. Effect of Isoniazid Therapy for Latent Tuberculosis Infection on QuantiFERON-TB Gold In-tube Responses in Tuberculin Skin Test Positive Adults in a High Tuberculosis Incidence Area: A Controlled Study. Chest. 2013 Oct 17. doi: 10.1378

 


Contact details:

South African Tuberculosis Vaccine Initiative 
Room S2.01
Wernher and Beit South Building 
Faculty of Health Sciences
University of Cape Town
Anzio Road, Observatory 7925

Tel: +27 21 406 6791
Fax:+27 21 406 6081
Email: Mark.Hatherill@uct.ac.za 

Alternate site
http://www.satvi.uct.ac.za

eResearch Portal for further details [link later]